Psoriatic Arthritis

In an abstract presented at EULAR 2020, investigators find more serious adverse events in the upadacitinib treatment arms compared to placebo.

Patients report sustained improvements in pain and fatigue from taking ixekizumab every 2 or 4 weeks over 3 years.

In both DISCOVER trials, investigators find guselkumab effective against active psoriatic arthritis domains.

The sBLA indication is the fifth for the IL17A inhibitor, which showed reduction of inflammatory signs and symptoms in treated patients at 52 weeks.

A new analysis of data from Northwestern Medicine found some chronic inflammatory diseases were associated with a 7-fold increase in risk of heart failure.

Doses of secukinumab are clinically safe and beneficial for long-term treatment of psoriatic arthritis.

Rheumatology patients are more susceptible to infections, making self-quarantining extremely important for this population.

Patients with psoriatic arthritis are not at an increased risk of cancer, however.

Findings of a phase 3 clinical trial show that patients who take a 15 mg or 30 mg dose achieved higher ACR20, ACR50, and ACR70 scores than those who had a placebo.

Biologics, JAK inhibitors, and opioid alternatives all served major payoffs in the field in the 2010s.

How therapies are advancing treat-to-target strategies, while the field faces a physician shortage issue.

Philip Mease, MD, director of rheumatology research at the Swedish Rheumatology Research Group, discusses the current state of treatments for psoriatic arthritis.

Elaine Husni, MD, discusses the results of a trial she led examining quality of life changes in psoriatic arthritis patients receiving golimumab over a 1-year period.

Philip Mease, MD, Director of Rheumatology Research at the Swedish Rheumatology Research Group, discusses why he believes some rheumatologists are skeptical of JAK inhibitors and where they fit in current treatment algorithms.

Full 52-week results of the SPIRT-H2H trial were presented during the late breaking session at ACR 2019.

Philip Mease, MD, Director of Rheumatology Research at Swedish Rheumatology Research Group, reflects upon new data and discusses where he sees guselkumab fitting into a PsA patient's current treatment plan.

Elaine Husni, MD, discusses how she goes about choosing which therapy is most appropriate for a patient with psoriatic arthritis.

A post hoc analysis of the OPAL Beyond and OPAL Broaden studies found tofacitinib improved skin-related symptoms and health-related quality of life in psoriatic arthritis patients with an inadequate response to csDMARDs or TNFi treatment.

A study from CCR West 2019 has found that tofacitinib can cut the time to clinically significant pain improvement in psoriatic arthritis patients by nearly half the time when compared to placebo therapy.

Biologics that target the immune system give doctors an opportunity to treat diseases like psoriasis and atopic dermatitis.

The human monoclonal antibody was previously approved for the treatment of adults with plaque psoriasis in July 2017.

A new set of guidelines has been released by the American College of Rheumatology, Spondylitis Association of America and the Spondyloarthritis Research and Treatment Network are offering guidance to physicians on treating axial spondyloarthritis.

The FDA suggests only limited use of tofacitinib to treat rheumatoid arthritis, ulcerative colitis, or psoriatic arthritis.

Investigators found positive results when examining the safety and efficacy of filgotinib in the FINCH 2 phase 3 clinical trial.

A pair of phase 3 studies showed 20% symptomatic improvement in patients with psoriatic arthritis who were treated with guselkumab.

A trio of phase 3 psoriatic arthritis trials showed that 30 mg of apremilast, twice daily, increased the likelihood of achieving low disease activity or remission.

Interim results at 24 weeks show that 75.3% of patients treated with tildrakizumab achieved a 20% improvement compared to 50.6% with placebo.

A FUTURE 5 trial and MAXIMIZE trial demonstrate that Cosentyx frequently stops radiographic progression and lessens axial manifestations, respectively.

Ixekizumab (Talz) was significantly more likely to both reduce disease activity by ≥50% and achieve complete skin clearance than adalimumab (Humira).

Risankizumab (Skyrizi) is now approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.